J. Goldman & Co’s Insmed INSM Stock Holding History

J. Goldman & Co’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-121,800	Closed	-$8.41M	–	547
2024 Q4	$8.41M	Buy	+121,800	New	+$8.77M	0.22%	139
2024 Q3	–	Sell	-20,000	Closed	-$1.34M	–	531
2024 Q2	$1.34M	Sell	20,000 -81,000	-80%	-$3.14M	0.04%	284
2024 Q1	$2.74M	Buy	+101,000	New	+$2.83M	0.09%	196
2020 Q4	–	Sell	-31,300	Closed	-$1.01M	–	422
2020 Q3	$1.01M	Buy	+31,300	New	+$900K	0.07%	214
2018 Q3	–	Sell	-90,000	Closed	-$2.13M	–	326
2018 Q2	$2.13M	Buy	+90,000	New	+$2.32M	0.11%	206
2018 Q1	–	Sell	-32,500	Closed	-$1.01M	–	392
2017 Q4	$1.01M	Buy	32,500 +6,500	+25%	+$192K	0.05%	235
2017 Q3	$811K	Buy	+26,000	New	+$495K	0.04%	247
2014 Q3	–	Sell	-96,300	Closed	-$1.92M	–	304
2014 Q2	$1.92M	Buy	+96,300	New	+$1.43M	0.14%	150
2014 Q1	–	Sell	-5,000	Closed	-$85K	–	263
2013 Q4	$85K	Buy	+5,000	New	+$76.6K	0.01%	206

Other funds holding INSM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

J. Goldman & Co's INSM Position: Q2 2026 in Review

J. Goldman & Co sold out of Insmed (INSM) in Q2 2026, closing a stake of 5,545 shares — an estimated $907K sold.

J. Goldman & Co first reported a position in INSM in Q4 2013 and held it in 25 quarters. The position peaked at $7.19M in Q4 2024. 667 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

J. Goldman & Co reported no remaining Insmed position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 5,545 Insmed shares in Q2 2026, an estimated $907K.
J. Goldman & Co first reported a position in Insmed in Q4 2013 and held it in 25 quarters.
J. Goldman & Co's Insmed position peaked at $7.19M in Q4 2024.
667 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.